Aeras Global TB Vaccine Foundation
Latest From Aeras Global TB Vaccine Foundation
GlaxoSmithKline has published results from its latest Phase IIb trial of its investigational tuberculosis vaccine that show a subunit vaccine can reduce pulmonary TB, possibly leading the way for the first new vaccine for TB in over 90 years.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Vaccitech's potential universal flu vaccine based on prime-boost technology is in early clinical trials in the UK, with partners likely to be sought for later-stage clinical studies; the company has just raised £20m in a Series A round from private investors that included Google's VC arm, GV, and Sequoia China.
Vaxxas thinks its vaccine-enhancement technology platform, Nanopatch, can bring in milestones and royalties just like a biotech drug candidate by offering increased potency and easier administration to makers of vaccines.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.